drugset / Trial / NCT07796217

Summary

The study aims to conduct a randomized controlled trial among adults aged 19 years or older who have experienced acute myocardial infarction at least one year prior, or who have other comorbidities such as peripheral arterial disease or multiple cardiovascular diseases, and have consented to participate in the study. Participants will be randomly assigned to either a group that maintains antiplatelet therapy with aspirin and clopidogrel or clopidogrel alone, or a group that maintains combined antiplatelet and anticoagulant therapy with aspirin and low-dose rivaroxaban in a 1:1 ratio. The study aims to demonstrate that maintaining clopidogrel-based antiplatelet therapy is not clinically inferior to maintaining combined therapy with aspirin and low-dose rivaroxaban.

Timeline

Start
2023-11-15
Primary completion
2027-06-30
Completion
2027-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aspirin Small molecule — —
Comparator Clopidogrel Small molecule — —
Subject Rivaroxaban Other / unclassified 2.5 mg —